IGHG3 and prostate cancer: IGHG3 specifically has also been shown to be overexpressed in a number of cancers, again predominantly epithelial tumours, including non-squamous non-small cell lung cancer [24,48], breast cancer [23,52], prostate cancer [22], malignant mesothelioma [21] and CRC [51,53].